0001209191-19-057610.txt : 20191121
0001209191-19-057610.hdr.sgml : 20191121
20191121162110
ACCESSION NUMBER: 0001209191-19-057610
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191119
FILED AS OF DATE: 20191121
DATE AS OF CHANGE: 20191121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEIDEN JEFFREY M
CENTRAL INDEX KEY: 0001242825
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 191237634
MAIL ADDRESS:
STREET 1: 40 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-11-19
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001242825
LEIDEN JEFFREY M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
1
0
0
CEO & President
Common Stock
2019-11-19
4
M
0
64032
109.14
A
170378
D
Common Stock
2019-11-19
4
M
0
32502
131.89
A
202880
D
Common Stock
2019-11-19
4
S
0
62886
210.41
D
139994
D
Common Stock
2019-11-19
4
S
0
23033
211.43
D
116961
D
Common Stock
2019-11-19
4
S
0
10615
212.75
D
106346
D
Common Stock
440
I
401(k)
Stock Option (Right to Buy)
109.14
2019-11-19
4
M
0
64032
0.00
D
2025-02-02
Common Stock
64032
0
D
Stock Option (Right to Buy)
131.89
2019-11-19
4
M
0
32502
0.00
D
2025-07-20
Common Stock
32502
0
D
Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $210.41 (range $210.06 to $210.83).
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $211.43 (range $211.08 to $211.97).
Open market sales reported on this line occurred at a weighted average price of $212.75 (range $212.30 to $212.97).
Fully vested.
/s/ Omar White, Attorney-in-Fact
2019-11-21